JMD 2021 CME Program in Molecular Diagnostics
The JMD 2021 CME Program in Molecular Diagnostics is an annual program consisting of a series of at least 72 questions based on selected articles in the 2021 issues (Volume 23, Numbers 1-12) of The Journal of Molecular Diagnostics (JMD). Bimonthly exams, consisting of at least 12 questions that are based on selected articles appearing in each issue of the Journal, will be available online on AMPEDTM for registered participants.
To receive CME credit for this journal-based CME activity, participants must achieve a score of at least 75% on each bimonthly exam and complete a Post-Test Evaluation. All exams must be completed by December 31, 2021 to receive CME credit. Participants will earn 3.0 AMA PRA Category 1 Credit(s)™ for the successful completion of each bimonthly exam.
Pricing and How to Enroll
You must have an account in order to pay by credit card and access the course. Creating an account is free and easy and can be done by clicking the "New User? Click here" link on the login page.
Pay by Credit Card
Click on the enroll button and complete checkout
Click on the enroll button.
Click on the enroll button and complete checkout
The deadline for receipt of the JMD 2021 CME Program in Molecular Diagnostics Registration Form and online submission of answers and Evaluation Form is December 31, 2021.
Continuing Medical Education (CME)
CME Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the American Society for Clinical Pathology (ASCP) and the Association for Molecular Pathology (AMP). The ASCP is accredited by the ACCME to provide continuing medical education for physicians.
CME Credit Designation StatementThe ASCP designates this journal based CME educational activity for a maximum of 18.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
For more information please contact the AMP Education Office by phone at (301)634-7987; email (AMPEducation@amp.org).
Meeting Objective/Target Audience
The objective of the JMD 2021 CME Program in Molecular Diagnostics is to increase basic and applied pathology knowledge, focusing on the molecular pathogenesis, diagnosis, prognosis, and the treatment of disease. The JMD 2021 CME Program in Molecular Diagnostics is designed to meet the participants' education needs in the physician competency area of Medical Knowledge, as defined by the Accreditation Council for Graduate Medical Education (ACGME) and the American Board of Medical Specialties (ABMS), and to support participants' lifelong learning towards a goal of promoting patient safety and improving patient care. The program is specifically targeted to pathologists and laboratory professionals who practice molecular pathology and researchers investigating molecular mechanisms of disease, pathology residents and fellows in molecular genetic pathology training programs, and clinicians and researchers interested in advances in molecular diagnostics.
Upon completion of the JMD 2021 CME Program in Molecular Diagnostics, participants should be able to:
- discuss the research underway and/or current molecular approaches to the diagnosis and prognosis of inherited diseases and syndromes;
- discuss the research underway and/or current molecular approaches to pharmacogenetics, cytogenetics, DNA identity tests, and hematopathology (including clonality, translocations, and point mutations);
- discuss the research underway and/or current molecular approaches to the diagnosis and prognosis of solid and soft tissue tumors;
- discuss the research underway and/or current molecular approaches to the diagnosis of infectious diseases (including bacterial, fungal, viral, and parasitic pathogens);
- discuss the research underway and/or current molecular approaches to the diagnosis and prognosis of acquired diseases spanning systems biology;
- demonstrate a gained level of knowledge of the molecular methods and techniques being used by researchers and practitioners;
In order to ensure balance, independence, objectivity and scientific rigor in all its educational activities, and in accordance with ACCME Standards, the ASCP requires that all individuals in a position to influence and/or control the content of ASCP CME activities disclose to the ASCP and subsequently to learners whether they do or do not have any relevant financial relationships with proprietary entities producing health care goods or services that are discussed in CME activities.
Faculty are asked to use generic names in any discussion of therapeutic options, to base patient care recommendations on scientific evidence and to base information regarding commercial products/services on scientific methods generally accepted by the medical community. All ASCP CME activities are evaluated by participants for the presence of any commercial bias and thus input is used for subsequent CME planning decisions. The primary purpose of this journal-based CME activity is educational and the comments, opinions, and/or recommendations expressed by the faculty or authors are their own and not those of ASCP or ASIP.
The Planning Committee members and staff of this journal-based CME activity have no relevant financial relationships with commercial interest to disclose. Relevant financial relationships of the authors of selected articles in this journal-based CME activity will be disclosed in a footnote to the published article and in each examination.